• AstraZeneca Inks Europe Deal For 400M Covid-19 Vaccine Doses

    AstraZeneca Inks Europe Deal For 400M Covid-19 Vaccine DosesAstraZeneca (AZN) has agreed to supply up to 400 million doses of the University of Oxford’s COVID-19 vaccine, AZD1222, to Europe’s Inclusive Vaccines Alliance (IVA), with deliveries starting by the end of 2020.Total manufacturing capacity for AZD1222 now stands at two billion doses, says AZN.Spearheaded by Germany, France, Italy and the Netherlands, the IVA says it aims to accelerate the supply of the vaccine and to make it available to other European countries that wish to participate in the initiative.At the same time, UK-based AstraZeneca continues to build several global supply chains, including for Europe. “The company is seeking to expand manufacturing capacity further and is open to collaborating with other companies in order to meet its commitment to support access to the vaccine at no profit during the pandemic” AZN states.Pascal Soriot, CEO of AstraZeneca, commented: “With our European supply chain due to begin production soon, we hope to make the vaccine available widely and rapidly.”Indeed, the company recently entered similar agreements with the UK, US, the Coalition for Epidemic Preparedness Innovations and Gavi the Vaccine Alliance for 700 million doses. It has also agreed a license with the Serum Institute of India for the supply of an additional one billion doses for low and middle-income countries.Oxford University last month announced the start of a Phase II/III UK trial of AZD1222 in about 10,000 adult volunteers. Other late-stage trials are due to begin in a number of countries. AstraZeneca recognizes that the vaccine may not work but is nonetheless progressing the clinical program with speed and scaling up manufacturing at risk.AZD1222 uses a replication-deficient chimpanzee viral vector based on a weakened version of a common cold virus that causes infections in chimpanzees and contains the genetic material of SARS-CoV-2 spike protein. After vaccination, the surface spike protein is produced, priming the immune system to attack COVID-19 if it later infects the body.Shares in AstraZeneca are up 3% year-to-date, and analysts are, on average, predicting that 20% further upside potential lies ahead. This comes with a Strong Buy consensus based on 4 recent buy ratings. (See AstraZeneca stock analysis on TipRanks).Related News: Oxford Biomedica Clinches Manufacturing Deal For AstraZeneca’s Covid-19 Vaccine 5 Promising Covid-19 Vaccines Picked For Trump’s Operation Warp Speed What Would a Merger Mean for Gilead? Top Analyst Weighs In More recent articles from Smarter Analyst: * Medtronic Succeeds In Critical US Trial For New Insulin Pump * American Express Scores China Go-Ahead In Milestone Moment * Sorrento Edges Higher On Debt Repayment As Top Analyst Says Buy * Activist Investor Jana Partners Builds 5.9% Stake in Perspecta; Stock Jumps 9% In Pre-Market

    from Yahoo Finance https://ift.tt/2B7ZHiK

  • The most explosive ASX tech shares you can buy today

    tech shares

    On Saturday I looked at the healthcare sector and revealed how it has vastly outperformed the S&P/ASX 200 Index (ASX: XJO) over the last five years.

    It isn’t the only side of the market to have outperformed the index over the period. Another area which has been on fire has been the tech sector.

    During this time the S&P/ASX 200 Information Technology index has gained a sizeable 84.6%.

    But don’t worry if you missed these gains, because I believe the sector can continue to outperform over the next five years.

    But which shares should you buy? I believe the three ASX tech shares listed below have the potential to generate market beating returns for investors. Here’s why:

    Afterpay Ltd (ASX: APT)

    I think this payments company is an ASX tech share to buy with a long term view. Although its shares have been on fire this year, I still believe they can go materially higher in the future. This is due to the growing popularity of buy now pay later with consumers and retailers, its US$5 trillion opportunity in the United States, and expansion opportunities in mainland Europe and Asia. The latter could be supported by US$500 billion WeChat owner, Tencent Holdings. It recently became a substantial shareholder of Afterpay.

    Altium Limited (ASX: ALU)

    Another ASX tech share to consider buying is Altium. It is a printed circuit board design software company which is benefiting greatly from the rapidly growing Internet of Things (IoT) market. The explosion of connected devices globally has been driving increasing demand for its Altium Designer software. So much so, this year Altium expects to achieve 50,000 subscribers. After which, it is aiming for 100,000 subscribers by FY 2025. Together with its other promising businesses such as NEXUS and Octopart, I feel Altium is well-placed to deliver strong long term earnings growth.

    Appen Ltd (ASX: APX)

    I final ASX tech share to look at is Appen. The artificial intelligence (AI) company has a million-plus team of crowd-sourced experts which prepare the data to go into the AI and machine learning models of some of the world’s largest tech companies. This includes the likes of Facebook, Microsoft, and Apple. In respect to Apple, Appen helped the tech behemoth develop its intelligent assistant, Siri. The good news is that AI is growing in importance for businesses. I believe this means demand for its services will continue to grow over the next decade and underpin strong earnings growth.

    And here are more exciting shares which could be destined for big things…

    5 stocks under $5

    We hear it over and over from investors, “I wish I had bought Altium or Afterpay when they were first recommended by The Motley Fool. I’d be sitting on a gold mine!” And it’s true.

    And while Altium and Afterpay have had a good run, we think these 5 other stocks are screaming buys. And you can buy them now for less than $5 a share!

    *Extreme Opportunities returns as of June 5th 2020

    More reading

    James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of AFTERPAY T FPO and Altium. The Motley Fool Australia owns shares of Appen Ltd. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    The post The most explosive ASX tech shares you can buy today appeared first on Motley Fool Australia.

    from Motley Fool Australia https://ift.tt/3cZaNEd

  • Why the Healius share price will be in the spotlight tomorrow morning

    Looking through magnifying glass

    The Healius Ltd (ASX: HLS) share price will be in the spotlight tomorrow morning on reports that it sealed a $500 million deal on the weekend.

    The medical facilities operator agreed to sell its 70-odd medical centres to Australian private equity firm BGH Capital, reported the Australian Financial Review.

    The agreement, which is understood to be binding and fully funded, will make BGH the largest operator of general practice clinics in the country.

    Takeover defense

    These medical centres generated $183 million in revenue and $30 in earnings before interest, tax, depreciation and amortisation (EBITDA) in the six months to end December 2019, according to the AFR.

    The divestment is seen as a defensive strategy to impede the takeover of Healius by Partners Group, which offered $3.40 a share for all of the company back in February.

    Healius rejected the non-binding offer and it’s been a one-way street for its share price since as it slumped to $2.53 on Friday.

    Can Healius shares outperform?

    Management will be hoping for a big boost in the stock to justify the snub to shareholders. While it remains to be seen how the stock trades on Monday morning, history is on its side.

    ASX stocks that undertake a divestment tend to outperform and recent transactions, such as Wesfarmers Ltd (ASX: WES) cutting the apron strings of Coles Group Ltd (ASX: COL), could put Healius shareholders in a good mood.

    Healthcare sector underperformer

    That would be a refreshing change as there isn’t much goodwill floating about for Healius. The stock crashed 20% over the past year when its peers have been faring a lot better.

    The Ramsay Health Care Limited Fully Paid Ord. Shrs (ASX: RHC) share price gained around 2% while the Sonic Healthcare Limited (ASX: SHL) share price dipped 8% over the same period.

    In contrast, the S&P/ASX 200 Index (Index:^AXJO) lost 11% of its value, no thanks to the COVID-19 global market meltdown.

    Foolish takeaway

    I can’t help feeling that BGH got a better deal than Healius, assuming the centres are being acquired on a 10 times EBITDA multiple.

    While that’s within a reasonable range for acquisitions, some might argue that defensive assets in this ultra-low interest rate environment would be worth more.

    Healius is likely to use the proceeds from the asset sale to repay debt and to focus its resources on growing its pathology and diagnostic imaging business.

    The group had been trying to sell its medical centres since the start of the year before the coronavirus pandemic scared off some potential bidders.

    It may not be a big surprise that BGH emerged as the victor given that it raised a lot of capital in 2018 for its takeover fund and it already holds medical facilities in its portfolio.

    The acquisitive firm also owns now-delisted educational services group Navitas Limited (ASX: NVT) and is reported to be in talks with Village Roadshow Ltd (ASX: VRL) to acquire its theme parks.

    3 “Double Down” Stocks To Ride The Bull Market

    Motley Fool resident tech stock expert Dr. Anirban Mahanti has stumbled upon three under-the-radar stock picks he believes could be some of the greatest discoveries of his investing career.

    He’s so confident in their future prospects that he has issued “double down” buy alerts on each of these three stocks to members of his Motley Fool Extreme Opportunities stock picking service.

    *Extreme Opportunities returns as of June 5th 2020

    More reading

    Motley Fool contributor Brendon Lau has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of COLESGROUP DEF SET and Wesfarmers Limited. The Motley Fool Australia has recommended Ramsay Health Care Limited and Sonic Healthcare Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

    The post Why the Healius share price will be in the spotlight tomorrow morning appeared first on Motley Fool Australia.

    from Motley Fool Australia https://ift.tt/2UL9geK